Status:
RECRUITING
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Kartagener Syndrome
Eligibility:
All Genders
Brief Summary
The overall short-term goals of this project include the following: 1) identify the genes that are key to the function of respiratory cilia to protect the normal lung; and 2) the effects of genetic mu...
Detailed Description
A key component of lung defense is the efficiency of mucociliary clearance (MCC). Primary ciliary dyskinesia (PCD) is a human genetic disorder with defective MCC. This ongoing project is designed to ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients who have a high suspicion for the diagnosis of PCD, based on clinical features
- Healthy Volunteers who have a family member with confirmed PCD.
Exclusion
Key Trial Info
Start Date :
January 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
1800 Patients enrolled
Trial Details
Trial ID
NCT00807482
Start Date
January 1 2004
End Date
April 1 2027
Last Update
May 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599